eNews May 4, 2021The latest news affecting you and your customers… from the Independent Medical Specialty Dealers Association
How is COVID-19 affecting your business, your people, your customers? IMDA is a membership organization, and in times like these, we can all use some camaraderie. If you have a COVID story to share, advice to offer, or a warning to sound, send it to Mark Thill, IMDA’s communications director, at firstname.lastname@example.org, with the subject line “IMDA COVID story.” We’ll compile them and send them back out to you.
High-flow nasal oxygen guidelines
The American College of Physicians (ACP) released a new Clinical Guideline with recommendations for the appropriate use of high-flow nasal oxygen in hospitalized patients for initial or post-extubation management of acute respiratory failure. For the management of acute hypoxemic respiratory failure, ACP suggests clinicians use high-flow nasal oxygen rather than noninvasive ventilation (NIV). In hospitalized adults with post-extubation acute hypoxemic respiratory failure, ACP suggests clinicians use high-flow nasal oxygen rather than conventional oxygen therapy (COT). The guideline notes that more research is needed to identify which patients are most likely to benefit from HFNO, particularly by type of acute respiratory failure, as evidence was insufficient on patients with hypercapnia.
Researchers at Aalto University in Finland report they have developed an ultrasonically actuated needle that can retrieve a large amount of tissue during a biopsy. The device can house a conventional syringe with a fine needle. It vibrates the needle tip approximately 30,000 times per second, causing the tissue to behave more like a liquid, so more tissue can enter the fine needle. One of the issues with biopsies is the need to use wide bore needles to ensure that enough tissue is obtained for the required diagnostic tests, according to the researchers. Such needles can be painful and can cause bleeding.
The pandemic and respiratory care education
The pandemic drastically affected the ability of respiratory care education programs to provide high-quality educational experiences. A live AARC webcast on May 5 will focus on the changes to clinical education during the pandemic and how onboarding of new graduates into their careers has been affected. The panel will approach this topic from their unique perspectives in formal education, clinical education, and department leadership.
Augmented reality for cranial procedures
A partnership between Medtronic and Los Angeles-based Surgical Theater will allow neurosurgeons to use augmented reality (AR) to visualize structures in the brain, test virtual surgical tools and plan surgeries before entering the operating room. The combination of Medtronic’s StealthStation™ S8 and Surgical Theater’s SyncAR™ technology is designed to give surgeons the ability to see otherwise hidden anatomical and vascular structures, pathologies, and Diffusion Tensor Imaging (DTI) white matter tracts. A 360° AR rendering, created from the patient’s scans, is overlaid onto the live image viewed through the oculars of the microscope as they track the positioning of their surgical tools, allowing surgeons to keep their eyes focused on the patient.
Ambu Inc. received Health Canada clearance for the aScope™ 4 Cysto, the company’s flexible cystoscope platform for diagnosing, managing, and treating lower urinary disorders such as hematuria, incontinence and bladder cancer. The single-use cystoscope – which was cleared for marketing in the United States in April 2020 — is used with the company’s aView™ 2 Advance, a high-definition display for video endoscopy. The unit is said to be easily transported throughout the hospital, can be connected to EHR/EMR systems, and provides image and video procedure recording for documentation or for immediate review with the patient. The aView 2 Advance platform supports the company’s entire line of single-use flexible scopes for cystoscopy, bronchoscopy and rhinolargyngoscopy.
Remote glaucoma management
Implandata Ophthalmic Products, a digital health company with offices in Germany and San Diego, California, said its EYEMATE™ system for remote patient monitoring and management of glaucoma has obtained Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration. The system is intended to give patients the ability to measure their intraocular pressures from anywhere and anytime, and then automatically send that information to their doctor. Eighty million people with age-related chronic eye disease glaucoma suffer the risk of permanently losing vision, according to the company.
YOU’RE WORTH IT
Learn how to clarify and articulate your return-on-investment for your manufacturers and customers at this fall’s 2021 IMDA/HIRA Annual Conference, “ROI: It’s More Than Just Money,” Sept. 27-29, in suburban Chicago. You know you’re worth it. Now let everyone else know it too!